pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Alzheimer's Disease · news · pharmadog
← back to Alzheimer's Disease
News mentioning Alzheimer's Disease
26
stories
13h
#CTAD26: Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s
endpoints
20h
Biogen’s tau therapy drives bigger benefits in 2-year Alzheimer’s update
fiercebiotech
1d
Priavoid’s Alzheimer’s pill fails to prove efficacy in phase 2 trial
fiercebiotech
1d
Cognito phase 3 flops in light-and-sound Alzheimer's trial, but sees ‘signal’ for HOPE
fiercebiotech
1d
#CTAD26: Cognito plans FDA submission of light and sound therapy for Alzheimer’s
endpoints
1d
CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy
biospace
2d
AriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing option
fiercebiotech
9d
J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
fiercebiotech
12d
This week in charts: 3 drug launches Wall Street is watching
biopharma dive
20d
Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
fiercebiotech
20d
BMS walks away from $80M neurodegeneration bet after phase 1
fiercebiotech
27d
FDA Launches New Program to Advance Neuroscience Medical Product Development
fda press
29d
BMS leads Pathos AI's $237M series E alongside Alzheimer's link-up
fiercebiotech
Oct 19, 26
Pathos inks BMS, Tempus collabs to apply agentic AI in Alzheimer's clinical development
fiercebiotech
Oct 6, 26
The top biopharma conferences in 2027
biopharma dive
Sep 24, 26
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
fiercebiotech
Aug 25, 26
Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test
biopharma dive
Aug 24, 26
Roche, Eli Lilly net FDA approval for first-of-its-kind Alzheimer’s biomarker blood test
fiercebiotech
Aug 17, 26
FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify
fiercebiotech
Aug 14, 26
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
fiercebiotech
Aug 11, 26
CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaques
fiercebiotech
Aug 6, 26
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
Jul 27, 26
MapLight dives despite positive data for schizophrenia drug
biopharma dive
Jul 14, 26
Biogen's tau drug reports mixed Alzheimer's results, as low dose performs better
endpoints
Jul 14, 26
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
biopharma dive
Dec 23, 25
Fierce Biotech Layoff Tracker 2026: Milestone shrinks HQ workforce during Cardamyst rollout
fiercebiotech